RxDoctor Payments Data

Miloslava Kyncl, MD

Internal Medicine · Waukegan, ILNPI 1245223734

Payments from drug & device makers

$3,909in general payments, 2019–2025

Across 110 payments — averaging $35.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$790
  • Pfizer$511
  • Boston Scientific$423
  • Lilly USA, LLC$350
  • Boehringer Ingelheim$336
  • Corcept Therapeutics$331
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$3,898100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,909 in reported general payments places this provider in the 85th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$65,884
Medicare patients
125
Services billed
632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin52$51,342
FarxigaDapagliflozin Propanediol45$47,432
OzempicSemaglutide26$46,566
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$32,919
EliquisApixaban26$31,622
MounjaroTirzepatide24$29,398
XareltoRivaroxaban24$28,768
Humalog Kwikpen U-100Insulin Lispro35$15,836
JanuviaSitagliptin Phosphate19$13,086
MyrbetriqMirabegron17$11,097
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$9,054
LinzessLinaclotide13$7,275
VascepaIcosapent Ethyl17$5,598
SynthroidLevothyroxine Sodium59$5,486
Celecoxib81$3,823

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$336$51,34252 claims
AstraZenecaFarxiga$209$47,43245 claims
Novo NordiskOzempic$790$46,56626 claims
GSKTrelegy Ellipta$38$32,91927 claims
PfizerEliquis$511$31,62226 claims
Lilly USA, LLCMounjaro$350$29,39824 claims
Johnson & JohnsonXarelto$31$28,76824 claims
AbbVieLinzess, Synthroid$24$12,76172 claims
Sanofi-aventis U.S. LLCLantus$42$1,18413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Waukegan

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →